Valuation: Bolt Biotherapeutics, Inc.

Market Cap 7.06M 6.05M 5.66M 5.18M 9.72M 676M 9.85M 66.86M 26.07M 339M 26.51M 25.93M 1.12B P/E 2026 *
-0.16x
P/E 2027 * -0.18x
Enterprise Value 7.06M 6.05M 5.66M 5.18M 9.72M 676M 9.85M 66.86M 26.07M 339M 26.51M 25.93M 1.12B EV / Sales 2026 *
35.3x
EV / Sales 2027 * 2.02x
Free-Float
96.53%
Yield 2026 *
-
Yield 2027 * -
1 day+14.53%
1 week+9.40%
Current month-8.15%
1 month-8.83%
3 months-20.15%
6 months-27.43%
Current year-32.97%
1 week 3.15
Extreme 3.15
3.78
1 month 3.13
Extreme 3.13
4.15
Current year 3.13
Extreme 3.13
7.2
1 year 3.13
Extreme 3.13
7.2
3 years 3.13
Extreme 3.13
31.2
5 years 3.13
Extreme 3.13
385.7
10 years 3.13
Extreme 3.13
861.4
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer - 14/05/2024
Chief Executive Officer 55 14/05/2024
Chief Operating Officer 61 14/05/2024
Director TitleAgeSince
Director/Board Member 64 30/11/2020
Director/Board Member 55 14/05/2024
Chairman 56 03/09/2024
Date Insider Type Main position Quantity % Market Cap.
10/06/26 Free

Chairman

5,000 0.2602%
28/01/26 Free

Chief Operating Officer

10,000 0.5210%
28/01/26 Buy

Chief Executive Officer

20,125 1.0485%
Change 5-day change 1-year change 3-year change Capi.($)
+14.53%+9.40%-25.05%-84.07% 7.06M
-3.00%+2.27%+77.60%+109.33% 72.12B
+1.90%+23.53%+56.60%+97.76% 65.85B
+5.12%+25.22%+5.24%-0.82% 29.28B
+0.55%+1.64%-5.15%+471.68% 27.47B
+2.74%+12.98%+62.84%+28.14% 26.7B
+0.47%+6.12%+36.66%-13.79% 20.06B
+1.82%-6.67%+247.46%+393.10% 18.22B
+0.94%+3.36%+18.55%+532.94% 16.4B
+0.73%+5.54%+39.71%+153.07% 13.4B
Average +2.58%+8.47%+51.44%+168.74% 28.95B
Weighted average by Cap. +0.74%+9.48%+59.04%+157.80%

Financials

2026 *2027 *
Net sales 200K 171K 160K 147K 275K 19.14M 279K 1.89M 739K 9.61M 751K 735K 31.8M 3.5M 3M 2.81M 2.57M 4.82M 335M 4.88M 33.14M 12.92M 168M 13.14M 12.86M 556M
Net income -47.4M -40.6M -37.99M -34.78M -65.27M -4.54B -66.13M -449M -175M -2.28B -178M -174M -7.54B -47.5M -40.69M -38.07M -34.85M -65.4M -4.54B -66.27M -450M -175M -2.28B -178M -174M -7.55B
Net Debt - -
Logo Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing immunotherapies for the treatment of cancer. The Company’s pipeline includes BDC-3042, an agonist antibody that activates macrophages by targeting dectin-2, and BDC-4182, a next generation Boltbody Immune-Stimulating Antibody Conjugate (ISAC) clinical candidate targeting claudin 18.2. BDC-3042 is in a Phase I dose escalation trial that includes patients with any of seven different solid tumor types. The Company’s Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. It has two additional ISAC programs utilizing its Boltbody ISAC technology platform in preclinical development. One is a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5 (CEA). Its final Boltbody ISAC program targets PD-L1. The Company is also developing additional Boltbody ISACs in strategic collaborations with biopharmaceutical companies.
Employees
23
Date Price Change Volume
21/08/26 US$3.665 +14.53% 65,147
20/08/26 US$3.200 -1.84% 22,008
19/08/26 US$3.260 +2.60% 21,148
18/08/26 US$3.177 -0.71% 7,335
17/08/26 US$3.200 -4.48% 24,576
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
3.665USD
Average target price
29.00USD
Spread / Average Target
+691.27%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BOLT Stock